|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data reveal that MBL may impact on tumor development by shaping the tumor microenvironment <i>via</i> its interaction with the local stromal cells, and also suggests its potential therapeutic use for the treatment of HCC.
|
30713782 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Through integration of genomics, bioinformatics, and proteomics, the current study aims to shed light at the proteomic-related molecular events responsible for MBL pathophysiology, as well as to provide molecular/protein/pathway answers concerning tumor-onset.
|
25543836 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The murine T-cell lymphoma line, MBL2, and human cutaneous T-cell lymphoma (CTCL) lines, HH and Hut78, were used in syngeneic or standard NSG mouse models to demonstrate a marked suppression of tumor growth by rapamycin accompanied by inhibition of mTORC1/2.
|
25897830 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Evidence is presented linking biotinylation of heat-shock proteins HSP60 and HSP72 with redox biology and immune function, respectively, and biotinylation of the two ENO1 gene products MBP-1 and ENO1 with tumor suppression and glycolysis, respectively.
|
24684412 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combination of 10 mg/kg MBL-II-141 with the anticancer agent CPT-11 completely blocked the growth of 90% freshly implanted ABCG2-positive tumors.
|
25474134 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Downregulation of tumor suppressor MBP-1 by microRNA-363 in gastric carcinogenesis.
|
23975832 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cell viability, apoptosis, RT-PCR and Western blot assays were used to detect changes in tumor cell viability, apoptosis, and gene expression, respectively, after treatment of thyroid cancer cells with rhMBL.
|
23250731 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results demonstrate that malignant cells adapt to hypoxia by modulating alpha-enolase/MBP-1 levels and suggest a mechanism for tumor cell induction of the hyperglycolytic state.
|
20412594 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, it cannot be excluded that mbl-2 mutant alleles may be in linkage disequilibrium with an unidentified tumour susceptibility gene(s).
|
17131120 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One alternative translated product of the ENO1 gene, known as MBP-1, acts as a negative regulator of the c-myc oncogene, making the ENO1 gene a candidate as a tumour suppressor gene.
|
16359544 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We propose that MBP1 is the product of a candidate oncogene as rates of both neoplastic transformation and tumour cell growth were shown to be significantly enhanced when the protein is ectopically overexpressed.
|
10380882 |
1999 |